Valproate vs levetiracetam in juvenile myoclonic epilepsy: systematic review and meta-analysis.

Epilepsy BehavJul 23, 2026 (epub)
Clinical ResearchNeurology

Lavínia Voss Agra, Marcela Caracas Machado Borges, Luiz Carlos Fonseca de Azevedo Oliveira et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and tolerability of valproate (VPA) versus levetiracetam (LEV) in juvenile myoclonic epilepsy (JME) patients. Analyzing seven studies with 1,009 patients, VPA showed higher seizure remission rates (344 of 574 vs. 169 of 390; RR 1.44, 95% CI 1.27-1.63) and lower treatment discontinuation rates compared to LEV, although substantial heterogeneity was noted.

Key findings

  • VPA was associated with higher seizure remission rates compared to LEV (RR 1.44, 95% CI 1.27-1.63).
  • VPA had a lower risk of drug failure or treatment discontinuation (RR 0.68, 95% CI 0.54-0.86).
  • VPA was linked to a higher risk of memory impairment (RR 5.37, 95% CI 2.05-14.04).
  • VPA also showed a higher risk of weight gain or obesity (RR 6.40, 95% CI 3.64-11.26).

Why it matters

Understanding the comparative efficacy and side effect profiles of VPA and LEV is crucial for clinicians managing JME, particularly given the chronic nature of the condition and the need for long-term treatment strategies.

What to keep in mind

Substantial heterogeneity and the predominance of observational studies limit the confidence in the findings.

Source

Published in Epilepsy Behav. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.